Navigating Complexity in Biologics Development, Manufacturing, and Compliance

Experience excellence in technical, regulatory consultation, and guidance services for biologics and biotechnology.

Biologics — including monoclonal antibodies, cell and gene therapies, vaccines, and biosimilars — represent some of the most innovative and complex products in the life sciences industry. Their development and regulation require specialized expertise, robust quality systems, and strategic regulatory planning. Lachman Consultants supports biologics manufacturers across the globe with deep experience in -regulated products, helping clients meet evolving expectations from the FDA, EMA, and other global health authorities.

Biologics Photo

Who We Serve

  • Biotech startups and emerging biologics developers
  • Commercial biologics manufacturers
  • Cell and gene therapy companies
  • Vaccine developers
  • Biosimilar manufacturers
  • Contract development and manufacturing organizations (CDMOs)

How Lachman Supports Biologics Clients

Lachman Consultants brings cross-functional expertise in regulatory affairs, quality systems, and scientific strategy to biologics programs at every stage — from early development to post-market compliance.

We help clients:

  • Design and assess biologics manufacturing processes and control strategies, including sterile manufacturing environments
  • Conduct risk assessments and develop/enhance contamination control strategies (EU Annex 1)
  • Navigate regulatory pathways for biosimilars, ATMPs, and combination products
  • Prepare and submit INDs, BLAs, and global marketing applications
  • Respond to regulatory agency feedback, including 483s and Warning Letters
  • Align quality systems with biologics-specific GMP requirements
  • Train teams on biologics compliance, data governance, and inspection readiness

Key Challenges We Help Address in the Biologics Sector

  • Complex manufacturing processes and variability in biologic products
  • Regulatory divergence between FDA and EMA, especially for cell and gene therapies
  • Navigating the Biologics License Application (BLA) process
  • Immunogenicity, comparability, and stability concerns
  • Data governance and data integrity
  • Contamination control strategies (CCS) in biologics facilities